An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine/docetaxel for nonmuscle-invasive bladder cancer.

•GEM/DOCE appears to be effective for therapy naïve and patients who have failed previous intravesical therapies•DFS was 49% at 1 year and 29% at 2 years for all patients treated with GEM/DOCE.•Patients who demonstrate initial complete response to GEM/DOCE may benefit from maintenance GEM/DOCE.